Skip To Main Content
Xinying Luo on Muck Rack

Xinying Luo

As seen in: Wiley Online Library, ACS Publications, Royal Society of Chemistry, Dove Medical Press
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Xinying

Contact Xinying, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Synthesis of 1,1′-Biaryl-5,5′-Bis-1,2,3-Triazoles by t -BuOK-Promoted Reactions of 1,4-Bis(trimethylsilyl)butadiyne With Aryl Azides and Their Conversion to 3H -Bis-1,2,3-Triazolo Quinolines Through Oxidative Coupling

|
By Yibin Wang, Xinying Luo, Liuran Li
| Wiley Online Library Verified
Conflicts of Interest The authors declare no conflicts of Interest. Data Availability Statement The data that supports the findings of this study are available in the Supporting Information of this article.
Open in Who Shared Issue with article?

Tumor Assembloids as Three-Dimensional Platforms for Modeling Drug Delivery Barriers: Construction Strategies, Applications, and Translational Challenges

|
By Jiankang Zhang, Xinying Luo, Zhongyi Sun
| Dove Medical Press
Back to Journals » Drug Design, Development and Therapy » Volume 20 Authors Zhang J , Luo X , Sun Z, Jin B , Zhao Y Received 21 April 2026 Accepted for publication 3 July 2026 Published 14 July 2026 Volume 2026:20 618870 DOI https://doi.org/10.2147/DDDT.S618870 Checked for plagiarism Yes Review by Single anonymous peer review Peer reviewer comments 2 Editor who approved publication: Dr Muzammal Hussain Jiankang Zhang,1 Xinying Luo,1 Zhongyi Sun,1 Bohao Jin,1 Yunqi Zhao1– 4 1Department of...
Open in Who Shared Issue with article?

Harnessing organoid platforms for nanoparticle drug development

|
By Xinying Luo, Jiankang Zhang, Jinwen Zhang, Linanni Chen
| Dove Medical Press
Introduction The advent of nanotechnology has heralded a new era in the field of cancer treatment, with nanoparticles emerging as promising candidates for improving efficacy and reducing side effects.1 Despite the promise of nanoparticles in preclinical studies, translating these nanoscale drug delivery systems into clinical practice has been slow. Accurately evaluating the safety and efficacy of nanomedicine in preclinical studies is still a challenge.
Open in Who Shared Issue with article?
See all 7 articles